

Unicentre CH-1015 Lausanne http://serval.unil.ch

Year : 2022

Transfert inter-hospitalier héliportés des patientes souffrant d'une hémorragie du post-partum

Giacalone Sylvia

Giacalone Sylvia, 2022, Transfert inter-hospitalier héliportés des patientes souffrant d'une hémorragie du post-partum

Originally published at : Thesis, University of Lausanne

Posted at the University of Lausanne Open Archive <u>http://serval.unil.ch</u> Document URN : urn:nbn:ch:serval-BIB_2E6F694D90102

Droits d'auteur

L'Université de Lausanne attire expressément l'attention des utilisateurs sur le fait que tous les documents publiés dans l'Archive SERVAL sont protégés par le droit d'auteur, conformément à la loi fédérale sur le droit d'auteur et les droits voisins (LDA). A ce titre, il est indispensable d'obtenir le consentement préalable de l'auteur et/ou de l'éditeur avant toute utilisation d'une oeuvre ou d'une partie d'une oeuvre ne relevant pas d'une utilisation à des fins personnelles au sens de la LDA (art. 19, al. 1 lettre a). A défaut, tout contrevenant s'expose aux sanctions prévues par cette loi. Nous déclinons toute responsabilité en la matière.

Copyright

The University of Lausanne expressly draws the attention of users to the fact that all documents published in the SERVAL Archive are protected by copyright in accordance with federal law on copyright and similar rights (LDA). Accordingly it is indispensable to obtain prior consent from the author and/or publisher before any use of a work or part of a work for purposes other than personal use within the meaning of LDA (art. 19, para. 1 letter a). Failure to do so will expose offenders to the sanctions laid down by this law. We accept no liability in this respect.



UNIVERSITE DE LAUSANNE - FACULTE DE BIOLOGIE ET DE MEDECINE Département des centres interdisciplinaires

Service des Urgences

Transfert inter-hospitalier héliportés des patientes souffrant d'une hémorragie du post-partum

THESE

préparée sous la direction du Docteur Mathieu Pasquier

et présentée à la Faculté de biologie et de médecine de l'Université de Lausanne pour l'obtention du grade de

DOCTEUR EN MEDECINE

par

Sylvia GIACALONE

Médecin diplômée d'Italie Originaire de Aoste (Italie)

> Lausanne 2021

Unil UNIL | Université de Lausanne

Faculté de biologie et de médecine Ecole Doctorale Doctorat en médecine

Imprimatur

Vu le rapport présenté par le jury d'examen, composé de

Directeur.trice de thèse

Dr Mathieu François Pasquier

Co-Directeur.trice de thèse

Expert.e

Prof. David Baud

Vice-Directeur de l'Ecole doctorale

Prof. John Prior

la Commission MD de l'Ecole doctorale autorise l'impression de la thèse de

Madame Sylvia Giacalone

intitulée

Transfert inter-hospitalier héliportés des patientes souffrant d'une hémorragie du post-partum

Lausanne, le 3 février 2022

pour Le Doyen de la Faculté de Biologie et de Médecine Monsiour la Protessour, John Prior

Monsieur le Professeur John Prior Vice-Directeur de l'Ecole doctorale ELSEVIER

Contents lists available at ScienceDirect

European Journal of Obstetrics & Gynecology and Reproductive Biology



journal homepage: www.elsevier.com/locate/euro

Clinical characteristics and haemodynamic state of patients undergoing interhospital transfer for postpartum haemorrhage: A study of a singlecentre helicopter emergency medical service



S. Giacalone^a, A. Kottmann^{a,b}, V. Darioli^a, P.N. Carron^a, D. Desseauve^c, R. Albrecht^b, M. Pasquier^{a,*}

^a Emergency Department, Lausanne University Hospital, and University of Lausanne, Lausanne, Switzerland

^b Swiss Air Ambulance (Rega), Zürich, Switzerland

^c Department of Gynaecology and Obstetrics, Lausanne University Hospital, and University of Lausanne, Lausanne, Switzerland

ARTICLE INFO

Article history: Received 24 June 2021 Revised 24 October 2021 Accepted 2 November 2021

Keywords: Emergency medical services Postpartum haemorrhage Uterine artery embolization

ABSTRACT

Objective: Uterine artery embolization is an attractive option for the management of postpartum haemorrhage, however it is not available in every hospital. We compared the clinical characteristics and haemodynamic state of patients with postpartum haemorrhage, before and after helicopter transfer to a tertiary hospital for possible uterine artery embolization. We also analysed whether the type of treatment could modify the outcome.

Study design: Between 1999 and 2019 in Switzerland, we retrospectively found 82 consecutive patients with postpartum haemorrhage who were transferred by a physician-staffed helicopter emergency medical service to the tertiary hospital for potential uterine artery embolization. The collected data included the type of delivery, estimated blood loss, shock index and blood lactate levels before transfer and at destination, uterine artery embolization rate and hospital mortality rate. Our primary outcome was to describe the clinical characteristics, outcomes and haemodynamic state of the patients with postpartum haemorrhage before and after helicopter transfer. Our secondary outcome was to report the treatments performed at the tertiary hospital. The collected data were analysed with Stata version 14 (Stata Corporation, College Station, TX, USA). Continuous data are compared by using the Student's *t*-test or the Mann-Whitney *U* test, as appropriate.

Results: We included 69 patients. Postpartum haemorrhage occurred after vaginal delivery in 38 cases (55%). Blood loss prior to transfer exceeded 2 L in 34% of cases. The median shock index was 1 (IQR 0.8–1.1) before transfer and 0.9 (IQR 0.8–1.1) after transfer (p = 0.41). The median lactate level was 2.9 mmol/L (IQR 2.1–6.8) before, and 2.1 mmol/L (IQR 1.55–3.5) after transfer (p = 0.90). Forty-four patients underwent uterine artery embolization (64%), with an overall success rate of 93%. One patient died (1.4%), from a haemorrhagic shock of abdominal origin.

Conclusions: Interhospital helicopter transfer of patients with postpartum haemorrhage to a tertiary hospital seems to be safe in our setting, despite a significant proportion of patients exhibiting signs of haemodynamic instability. Decision criteria would be helpful to better guide choices regarding the transfer of patients with postpartum haemorrhage.

© 2021 Elsevier B.V. All rights reserved.

Introduction

E-mail address: Mathieu.Pasquier@chuv.ch (M. Pasquier).

Postpartum haemorrhage (PPH) is defined as the loss of more than 500 ml of blood within 24 h after giving birth vaginally [1,2]. It is one of the main causes of maternal death worldwide [3] and is responsible for about 30% of maternal deaths in developing countries[4]. In developed countries, the maternal mortality rate is lower but rising (estimated at 2–10 per 100,000 births) [5].

Abbreviations: UAE, uterine artery embolization; HY, hysterectomy; HEMS, helicopter emergency medical service; PPH, postpartum haemorrhage; CHUV, university hospital of Lausanne; NACA, National advisory Committee on Aeronautics; ICU, intensive care unit; IQR, interquartile range; PRBC, packed red blood cells; SI, shock index.

^{*} Corresponding author at: Emergency Department, Lausanne University Hospital, University of Lausanne, BH 06, CHUV, 1011 Lausanne, Switzerland.

The management of PPH is standardized regardless of the aetiology of bleeding. It is based on pharmacological therapy (uterotonics) and surgical revision of the uterine cavity and genital tract (curettage, haemostatic suturing) with simultaneous treatment of haemorrhage and shock, including volemic resuscitation, administration of blood products, and prevention and treatment of coagulopathy [4,6,7]. In the case of failure of this initial management, further measures include mechanical tamponade with an intrauterine (Bakri) balloon, or uterine artery embolization (UAE) by interventional radiology, which is usually performed if available in haemodynamically stable patients [4,7,8]. Conservative surgical management (sutures or arterial ligatures) is another salvage solution. Emergent abdominal hysterectomy (HY) is usually considered a last-resort life-saving procedure for intractable PPH [6,7].

Because of its high success rate and low complication rate, its conservative approach, and its potential for avoiding HY and therefore preserving fertility in young women, UAE is an especially attractive option for the management of PPH [1,4,7,9–14]. However, this procedure is available only in hospitals with a high level of technical platform [7]. Interhospital transfer of patients is therefore required, which can be quite challenging because of the potential for haemodynamic instability [15].

We compared the clinical characteristics and haemodynamic state of patients with postpartum haemorrhage, before and after a helicopter transfer to a tertiary hospital for possible uterine artery embolization. We also analysed whether the type of treatment could modify the outcome.

Methods

Study design and population

The study was conducted in a 3200 km² area in which we count six secondary hospitals with maternity wards and the University Hospital of Lausanne with a tertiary level of care in obstetricsgynaecology. In the canton of Vaud, interhospital transfers of patients in critical condition are assumed by the Lausanne-based helicopter of Rega Swiss Air Ambulance, the major physicianstaffed helicopter emergency medical service (HEMS) in Switzerland.

In this retrospective study, all HEMS admissions were screened from 01 January 1999 to 31 December 2019. We included 69 patients who, after vaginal or caesarean delivery, had a PPH and were transferred to the University Hospital of Lausanne (CHUV) for potential UAE. We excluded 13 patients who experienced haemorrhage secondary to miscarriage, or voluntary termination of pregnancy (Fig. 1).

Data collection

The following patient data were collected to define the situation before transfer: age, gravidity, parity, comorbidities (related to the specific situation, for example, disturbances in placental development, history of PPH, or abortion), characteristics of the birth (type of delivery, use of instruments), and quantity of blood loss. Data were also obtained on the medical, surgical, and mechanical treatments received by patients in the secondary hospital.

For the prehospital/transport phase, we collected the prehospital National Advisory Committee on Aeronautics (NACA) severity score [16], as well as the need for drug administration during the flight according to the patient's haemodynamic condition at the beginning of the mission and on arrival at the "Centre hospitalier universitaire Vaudois" (CHUV). We used the shock index (SI), defined as the ratio of heart rate to systolic blood pressure, to determine the severity of the patient's condition and level of haemodynamic instability before and after transfer [17–20].

Finally, we also analysed the tertiary hospital stay, paying attention to the choice of treatment (surgical revision, UAE) and the delay in its performance, the outcome (survival), the duration of the intensive care unit (ICU) stay, and the patient's condition at discharge.

Prehospital data were retrieved from the HEMS medical chart, which is completed by the emergency physician prospectively at the end of every mission. Hospital data from the secondary hospital were retrieved from the discharge medical report, and data from the tertiary hospital were extracted from the patients' medical charts.

Objectives of the study

Our **primary outcome** was to describe the clinical characteristics and haemodynamic state of the patients with PPH before and after the helicopter transfer (HEMS) to the tertiary hospital for possible UAE. Our secondary outcome was to report the treatments performed at the tertiary hospital (UAE, HY, conservative) and how they affected the outcome.

Statistical analysis

The collected data were analysed with Stata version 14 (Stata Corporation, College Station, TX, USA). Continuous data are expressed as means and standard deviations (SDs) or as medians and interquartile ranges (IQRs) according to the data distribution and compared with the Student's *t*-test (normal distribution of the data) or the Mann-Whitney *U* test (non-normal distribution of the data), as appropriate. The vital parameters and laboratory values of patients at the transferring and receiving hospitals were compared using the Wilcoxon matched-pairs signed rank test. Categorical data are expressed as numbers and percentages and compared by using Pearson's chi-squared test (expected counts \geq 5) or Fisher's exact test (expected counts \leq 5). A bilateral P of < 0.05 was considered significant.

Ethical considerations

The study and data collection were approved by the Ethics Committee of the state of Vaud "CER-VD", Switzerland (project number 2020–01176).

Results

The mean age was 31 ± 5 years, and most patients had undergone their first (41%, n = 28) or second (37%, n = 25) pregnancy. Of the total sample, 55% of the PPH occurred after natural delivery, without the use of particular instruments. The total blood loss for the majority of the patients was more than 1500 ml (Table 1). Various pharmacological treatments and blood supplies had already been administered before transfer: almost the entire population received uterotonics drugs; 28 (41%) patients received fibrinogen, and 34% received tranexamic acid; the transfusion of packed red blood cells (PRBC) (51%) and fresh frozen plasma (FFP) (51%) was preferred over the use of vasoactive drugs and conservative surgery had been attempted for four patients (6%) (Table 2). The haemodynamic state showed that SI before transfer (available for 67 patient) was >1 in 27 (40%) and >1.4 in seven patients (10%). Lactate levels before transfer were available for eight patients it was >2 mmol/L in seven patients (88%, n = 7) and > 4 mmol/L in three.




Fig. 1. Flowchart of study patients.

Most patients had a NACA score of \geq 4 (66/69; 95%).Of the total sample, 91% (n = 60) were admitted to the shock room at the receiving hospital. The operational and medical characteristics of the HEMS interhospital transfer are shown in Table 3.

The evolution of the vital parameters and laboratory values of patients between the transferring and receiving hospitals is shown in Table 4.

UAE was the first-line treatment for 36 patients (Table 5) and was successful in 32 (success rate of 89%). One patient of 69 underwent HY (1.4%) after a failed UAE. UAE was also performed as the second-line treatment in eight patients, including once after a failed first UAE attempt. Overall, 44 patients underwent UAE (64%), of whom three experienced UAE failure (overall success rate of 93%).

Of the total sample, 7% of the patients required ICU after the procedure and the majority had a 1 day stay or even less.

All but one patient survived the PPH (mortality rate of 1.4%). This patient presented in the regional hospital with acute abdominal pain and haemorrhagic shock. She underwent a caesarean delivery at the regional hospital because of foetal distress. Two episodes of cardiac arrest occurred during surgery, and retroperi-

toneal bleeding of unknown origin was identified. The patient was transferred to the tertiary centre (CHUV), where rupture of a splenic aneurysm was diagnosed and treated by arterial embolization. The course was complicated and the patient subsequently died in the ICU 71 days after admission.

Discussion

Our findings indicate that more than 50% of our total sample demonstrated signs of haemodynamic instability prior to helicopter transfer, as shown by elevations in SI and the lactate rate and low base excess levels. Forty-four (64%) different patients underwent UAE at the receiving hospital, which included three UAE failures (overall success rate of 93%). The cause of death for the only patient who died was non-obstetrical bleeding.

UAE as a first-line treatment of PPH

Worldwide the incidence of PPH is about 3 in 1000 and has increased in recent years [21–23]. This is also true in Switzerland, where PPH occurs in about 3% of all deliveries and is severe (requiring blood transfusion and/or emergent HY) in about 0.1%

Table 1

Maternal and obstetrical characteristics of patients with postpartum haemorrhage (n = 69).

| Age, mean \pm SD 31 \pm 5 Age, range 19-43 Gravidity, n (%) 2 2 25 (37) 3 10 (15) \geq 4 5 (7) Parity, n (%) 7(10) 1 30 (44) 2 3 (34) 3 7 (10) 4 1 (1) Delivery, n (%) 38 (55) Caseare delivery 29 (42) Abortus 2 (3) Type of delivery instruments, n (%) 88 (55) Caseare delivery 2 (3) None 62 (90) Other instruments n (%) 82 (50) None 62 (90) Other instruments n (%) 83 (64) Maternal comorbidities, n (%) 43 (64) History of miscarriage 6 (9) History of psychiatric problems 2 (3) History of psychiatric problems 2 (3) History of psychiatric problems 2 (3) History of placental problems 2 (3) History of placental problems 2 (3) History of placental problems 2 (1) | ` | | |
|---|---|---------------------------|---------|
| Gravidity, n (%) 28 (41) 1 25 (37) 3 10 (15) ≥ 4 5 (7) Parity, n (%) 7(10) 1 30 (44) 2 3 (34) 3 7 (10) 4 1 (1) Delivery, n (%) 29 (42) Abortus 2 (3) Type of delivery instruments, n (%) 2 (3) None 62 (90) Other instruments ⁴ 4 (6) Forceps 3 (4) Maternal comorbidities, n (%) 43 (64) History of miscarriage 6 (9) History of caesarean delivery 5 (7) History of pPPH 4 (6) History of polacental problems 2 (3) History of polacental problems 2 (3) History of placental problems 2 (3) History of placental problems 2 (2) 1000-1499 12 (27) 1500-1999 6 (14) 2000-2999 9 (20) 3000-4000 614) 2000-2999 9 (20) 3000-4000 614) < | | | |
| | | | 19-43 |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | | |
| | | | |
| | | | |
| ≥4 			5 (7) | | 3 | 10 (15) |
| 1 30 (44) 2 23 (34) 3 7 (10) 4 1 (1) Delivery, n (%) 29 (42) Abortus 29 (42) Abortus 2 (3) Type of delivery instruments, n (%) 62 (90) Other instruments ^a 4 (6) Forceps 3 (4) Maternal comorbidities, n (%) 70 None 62 (90) Other instruments ^a 4 (6) Forceps 3 (4) Maternal comorbidities, n (%) 70 None 62 (90) Other instruments ^a 4 (6) History of miscarriage 6 (9) History of caesarean delivery 5 (7) History of placental problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) (11 (25) 1000-1499 12 (27) 1500-1999 6 (14) 2000-2999 9 (20) 3000-4000 6 (14) Number of children, n (%) 1 1 <t< td=""><td></td><td>≥ 4</td><td></td></t<> | | ≥ 4 | |
| 1 30 (44) 2 23 (34) 3 7 (10) 4 1 (1) Delivery, n (%) 29 (42) Abortus 29 (42) Abortus 2 (3) Type of delivery instruments, n (%) 62 (90) Other instruments ^a 4 (6) Forceps 3 (4) Maternal comorbidities, n (%) 70 None 62 (90) Other instruments ^a 4 (6) Forceps 3 (4) Maternal comorbidities, n (%) 70 None 62 (90) Other instruments ^a 4 (6) History of miscarriage 6 (9) History of caesarean delivery 5 (7) History of placental problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) (11 (25) 1000-1499 12 (27) 1500-1999 6 (14) 2000-2999 9 (20) 3000-4000 6 (14) Number of children, n (%) 1 1 <t< td=""><td></td><td>Parity, n (%)</td><td></td></t<> | | Parity, n (%) | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | | | 7(10) |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | 1 | |
| 3 7 (10) 4 1 (1) Delivery, n (%) 1 (1) Vaginal delivery 29 (42) Abortus 2 (3) Type of delivery instruments, n (%) 62 (90) Other instruments ^a 4 (6) Forceps 3 (64) Maternal comorbidities, n (%) 3 (64) Maternal comorbidities, n (%) 4 (6) None 4 (6) History of miscarriage 6 (9) History of caesarean delivery 5 (7) History of voluntary termination of pregnancy 4 (6) History of psychiatric problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) 1 (125) 1000-1499 12 (27) 1500-1999 6 (14) Number of children, n (%) 1 1 63 (97) 2 2 (3) APGAR score, median (IQR) 1 1 9 (6-9) 5 5 9 (7-10) | | 2 | |
| 4 $1(1)$ Delivery, n (%) 38 (55) Caesarean delivery 29 (42) Abortus 2 (3) Type of delivery instruments, n (%) 62 (90) Other instruments ^a 4 (6) Forceps 3 (4) Maternal comorbidities, n (%) 7 None 43 (64) History of miscarriage 6 (9) History of caesarean delivery 5 (7) History of caesarean delivery 5 (7) History of pychiatric problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) 11 (25) < 1000 11 (25) $1000-1499$ 12 (27) $1500-1999$ 6 (14) Number of children, n (%) 11 (25) $1000-2999$ 9 (20) $3000-4000$ 6 (14) Number of children, n (%) 1 1 63 (97) 2 2 (3) APGAR score, median (IQR) 1 1 10(10, 1) 5 1 | | 3 | • • |
| Delivery, n (%) 38 (55) Vaginal delivery 29 (42) Abortus 2 (3) Type of delivery instruments, n (%) 62 (90) None 62 (90) Other instruments ^a 4 (6) Forceps 3 (4) Maternal comorbidities, n (%) 70 None 43 (64) History of miscarriage 6 (9) History of caesarean delivery 5 (7) History of caesarean delivery 5 (7) History of voluntary termination of pregnancy 4 (6) History of placental problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) (11 (25) 1000 11 (25) 1000 10 (277) 1500-1999 6 (14) Number of children, n (%) (14) Number of children, n (%) (3 (97) 2 2 (3) APGAR score, median (IQR) (6-9) 1 min 9 (6-9) 5 min 9 (7-10) | | | • • |
| Vaginal delivery Caesarean delivery Abortus $38 (55)$ $29 (42)$ AbortusType of delivery instruments, n (%) None $62 (90)$ Other instrumentsaMone $62 (90)$ Other instrumentsaMaternal comorbidities, n (%) None $43 (64)$ History of miscarriageMaternal comorbidities, n (%) None $43 (64)$ History of caesarean deliveryHistory of caesarean delivery History of pychiatric problems $5 (7)$ History of pychiatric problems $2 (3)$ Other problemsb $2 (3)$ History of placental problems $4 (6)$ History of placental problems $1 (1)$ Blood loss in ml, n (%) $< 1000-1499$ $12 (27)$ $1500-1999$ $9 (20)$ $3000-4000$ $1 (25)$ $1000-1499$ $6 (14)$ $2000-2999$ $9 (20)$ $3000-4000$ Number of children, n (%) 2 1 2 Inin $9 (6-9)$ $5 min$ $9 (7-10)$ | | Delivery n (%) | - (1) |
| Caesarean delivery Abortus 29 (42) 2 (3) Type of delivery instruments, n (%) None 62 (90) Other instruments ^a 4 (6) Forceps 3 (4) Maternal comorbidities, n (%) None 43 (64) History of miscarriage 6 (9) History of caesarean delivery 5 (7) History of zeesarean delivery 5 (7) History of voluntary termination of pregnancy 4 (6) History of voluntary termination of pregnancy 4 (6) History of placental problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) 1 (25) 1000-1499 12 (27) 1500-1999 6 (14) 2000-2999 9 (20) 3000-4000 6 (14) Number of children, n (%) 1 1 2 2 2 2 2 3000-4000 63 (97) 2 2 2 3000-4000 63 (97) 2 2 2 <td></td> <td></td> <td>38 (55)</td> | | | 38 (55) |
| Abortus2 (3)Type of delivery instruments, n (%)62 (90)None62 (90)Other instrumentsa4 (6)Forceps3 (4)Maternal comorbidities, n (%)3 (64)Mistory of miscarriage6 (9)History of caesarean delivery5 (7)History of caesarean delivery5 (7)History of voluntary termination of pregnancy4 (6)History of psychiatric problems2 (3)Other problemsb2 (3)Other problemsb2 (3)History of placental problems1 (1)Blood loss in ml, n (%)11 (25)1000-149912 (27)1500-19996 (14)2000-29999 (20)3000-40006 (14)Number of children, n (%)1163 (97)22163 (97)22163 (97)22163 (97)2239 (6-9)5559 (7-10) | | | • • |
| Type of delivery instruments, n (%) 62 (90) None 62 (90) Other instruments ^a 4 (6) Forceps 3 (4) Maternal comorbidities, n (%) 3 (64) Mistory of miscarriage 6 (9) History of caesarean delivery 5 (7) History of caesarean delivery 5 (7) History of pPH 4 (6) History of pychiatric problems 2 (3) History of placental problems 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) 1 <1000 | | | • • |
| None $62 (90)$ Other instruments ^a $4 (6)$ Forceps $3 (4)$ Maternal comorbidities, n (%) $3 (64)$ None $43 (64)$ History of miscarriage $6 (9)$ History of caesarean delivery $5 (7)$ History of caesarean delivery $5 (7)$ History of pPH $4 (6)$ History of psychiatric problems $2 (3)$ Other problems ^b $2 (3)$ History of placental problems $1 (1)$ Blood loss in ml, n (%) $11 (25)$ $1000 - 1499$ $12 (27)$ $1500 - 1999$ $6 (14)$ Number of children, n (%) 1 1 2 2 $2 (3)$ APGAR score, median (IQR) 1 1 $9 (6-9)$ 5 min $9 (6-9)$ | | | 2(3) |
| Other instruments 4 (f) Forceps 3 (4)Maternal comorbidities, n (%) 3 (4)None 43 (64)History of miscarriage 6 (9)History of caesarean delivery 5 (7)History of caesarean delivery 5 (7)History of pPH 4 (6)History of voluntary termination of pregnancy 4 (6)History of psychiatric problems 2 (3)Other problems ^b 2 (3)History of placental problems 1 (1)Blood loss in ml, n (%) 1 (25) $1000-1499$ 12 (27) $1500-1999$ 6 (14) $2000-2999$ 9 (20) $3000-4000$ 6 (14)Number of children, n (%) 1 1 2 2 2 1 63 (97) 2 2 2 3 APGAR score, median (IQR) 1 min 1 min 9 (6–9) 5 min 9 (7–10) | | | 62 (90) |
| Forceps 3 (4) Maternal comorbidities, n (%) (4) None 43 (64) History of miscarriage 6 (9) History of caesarean delivery 5 (7) History of pPH 4 (6) History of voluntary termination of pregnancy 4 (6) History of psychiatric problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) (2) <1000-1499 | | | • • |
| Maternal comorbidities, n (%) 43 (64) None 43 (64) History of miscarriage 6 (9) History of caesarean delivery 5 (7) History of caesarean delivery 5 (7) History of PPH 4 (6) History of voluntary termination of pregnancy 4 (6) History of psychiatric problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) 1 (25) <1000-1499 | | | • • |
| None43 (64)History of miscarriage6 (9)History of caesarean delivery5 (7)History of caesarean delivery5 (7)History of PPH4 (6)History of voluntary termination of pregnancy4 (6)History of psychiatric problems2 (3)Other problems ^b 2 (3)History of placental problems1 (1)Blood loss in ml, n (%)11 (25) <1000 11 (25)1000-149912 (27)1500-19996 (14)2000-29999 (20)3000-40006 (14)Number of children, n (%)1163 (97)22 (3)APGAR score, median (IQR)11 min9 (6-9)5 min9 (7-10) | | * | J (4) |
| History of miscarriage 6 (9) History of caesarean delivery 5 (7) History of PPH 4 (6) History of voluntary termination of pregnancy 4 (6) History of psychiatric problems 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) 11 (25) <1000 | | | 43 (64) |
| History of caesarean delivery 5 (7) History of PPH 4 (6) History of voluntary termination of pregnancy 4 (6) History of psychiatric problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) 11 (25) 1000-1499 12 (27) 1500-1999 6 (14) 2000-2999 9 (20) 3000-4000 6 (14) Number of children, n (%) 1 1 2 (3) APGAR score, median (IQR) 1 min 1 9 (6-9) 5 min 9 (7-10) | | | • • |
| History of PPH 4 (6) History of voluntary termination of pregnancy 4 (6) History of psychiatric problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) 1 (1) <1000 | | | • • |
| History of voluntary termination of pregnancy 4 (6) History of psychiatric problems 2 (3) Other problems ^b 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) 11 (25) < 1000 11 (25) $1000-1499$ 12 (27) $1500-1999$ 6 (14) $2000-2999$ 9 (20) $3000-4000$ 6 (14) Number of children, n (%) 1 1 2 (3) APGAR score, median (IQR) 2 (3) 1 min 9 (6-9) 5 min 9 (7-10) | | | |
| History of psychiatric problems2 (3)Other problems2 (3)History of placental problems1 (1)Blood loss in ml, n (%)11 (25) <1000 11 (25) $1000-1499$ 12 (27) $1500-1999$ 6 (14) $2000-2999$ 9 (20) $3000-4000$ 6 (14)Number of children, n (%)63 (97) 2 2 (3)APGAR score, median (IQR)9 (6-9) 1 min9 (6-9) 5 min9 (7-10) | | | |
| Other problems 2 (3) History of placental problems 1 (1) Blood loss in ml, n (%) 1 (25) <1000 | | | • • |
| History of placental problems 1 (1) Blood loss in ml, n (%) 11 (25) <1000 | | | |
| Blood loss in ml, n (%) 11 (25) <1000 | | | |
| <1000 11 (25) 1000-1499 12 (27) 1500-1999 6 (14) 2000-2999 9 (20) 3000-4000 6 (14) Number of children, n (%) 1 63 (97) 2 (3) APGAR score, median (IQR) 1 min 9 (6-9) 5 min 9 (7-10) | | | 1(1) |
| 1000-1499 12 (27) 1500-1999 6 (14) 2000-2999 9 (20) 3000-4000 6 (14) Number of children, n (%) 63 (97) 2 2 (3) APGAR score, median (IQR) 9 (6-9) 1 min 9 (6-9) 5 min 9 (7-10) | | | |
| 1500-1999 6 (14) 2000-2999 9 (20) 3000-4000 6 (14) Number of children, n (%) 63 (97) 1 63 (97) 2 2 (3) APGAR score, median (IQR) 1 1 min 9 (6-9) 5 min 9 (7-10) | | | |
| 2000-2999 9 (20) 3000-4000 6 (14) Number of children, n (%) 63 (97) 1 63 (97) 2 2 (3) APGAR score, median (IQR) 1 1 min 9 (6-9) 5 min 9 (7-10) | | 1000–1499 | • • |
| 3000-4000 6 (14) Number of children, n (%) 63 (97) 1 2 (3) APGAR score, median (IQR) 2 1 min 9 (6-9) 5 min 9 (7-10) | | 1500–1999 | 6 (14) |
| Number of children, n (%) 63 (97) 1 63 (97) 2 2 (3) APGAR score, median (IQR) 9 (6-9) 1 min 9 (6-9) 5 min 9 (7-10) | | 2000–2999 | 9 (20) |
| 1 63 (97) 2 2 (3) APGAR score, median (IQR) 1 min 9 (6-9) 5 min 9 (7-10) | | 3000-4000 | 6 (14) |
| 2 2 (3) APGAR score, median (IQR) 1 min 9 (6-9) 5 min 9 (7-10) | | Number of children, n (%) | |
| APGAR score, median (IQR) 1 min 5 min 9 (6–9) 9 (7–10) | | 1 | 63 (97) |
| 1 min 9 (6–9) 5 min 9 (7–10) | | 2 | 2 (3) |
| 1 min 9 (6–9) 5 min 9 (7–10) | | APGAR score, median (IQR) | |
| 5 min 9 (7–10) | | 1 min | 9 (6-9) |
| | | 5 min | , , |
| | | 10 min | |
| | | | |

IQR = interquartile range; PPH = postpartum haemorrhage.

^a Vacuum extractor, spoon, spatula.

^b Prophylactic anticoagulation (n = 1), uterine fibroma ablation (n = 1), thalassemia minor (n = 1).

[24]. Emergency postpartum HY is a last-resort option in the management of PPH and generally proposed for patients in severe shock [22,24]. Although HY unavailability in some rural settings may be the reason to transfer a patient with PPH to a higher level centre [15], interhospital transfer for PPH is mostly indicated to avoid HY by offering patients conservative treatments, including UAE, at a proportion as high as 91% in some centres [24–30]. The rationale for transfer for PPH is the fertility-sparing potential of UAE, which is mostly important [7,8,24,29] for primiparous women [7,27], as well as to avoid the psychological impact of HY when it can be avoided [22,24].

The proportion of first-line treatment performed before transfer in our study was similar to that described in a previous study [31]. The global UAE success rate was 93% in our study, which is in the range of 79% to 100% reported by other teams [8,25–28,30]. Only one patient underwent re-embolization and one underwent HY after a failed UAE (1.4%), which is also similar to that reported in other studies [27–29,32]. Although it is not possible to determine if HY would have been necessary for every patient who underwent UAE in our study, we believe that a substantial proportion of HYs were prevented, considering the high proportion (61%) of patients who benefited from UAE in our cohort. This may have allowed for the preservation potential for subsequent pregnancies [8]. The suc-

European Journal of Obstetrics & Gynecology and Reproductive Biology 268 (2022) 48-55

Table 2

Management of patients with postpartum haemorrhage at the transferring hospital (n = 69).

| Uterine massage Surgery, n (%) | e, n (%) | 9 (13) |
|-----------------------------------|----------------------------------|---------|
| | Curettage | 35 (51) |
| | Surgery ^a | 4 (6) |
| | Genital surgical revision | 10 (14) |
| Blood products, | n (%) | . , |
| • | \geq 1 PRBC transfusion | 35 (51) |
| | FFP transfusion | 33 (48) |
| | >5 PRBC transfusions | 11 (16) |
| | Platelets transfusion | 6 (9) |
| Blood units, med | lian (IQR) | 2 (0-4) |
| Blood units, rang | ge | 0-12 |
| Coagulation/hae | mostatic factors | |
| | Fibrinogen | 28 (41) |
| | Tranexamic acid | 23 (34) |
| | Coagulation factors ^b | 7 (10) |
| Intravascular inf | usion, n (%) | |
| | Crystalloids | 30 (43) |
| | Colloids | 29 (42) |
| Uterotonics ^c , n (| %) | 60 (88) |
| Mechanical haer | nostasis ^d , n (%) | 21 (30) |
| Vasoactive drug | s ^e , n (%) | 4 (6) |

IQR = interquartile range; FFP = fresh frozen plasma; PRBC = packed red blood cells. ^a Surgical uterine artery ligature (n = 3), laparotomy (n = 1).

^b Haemostasis factors II, VII, IX, X (Prothrombine Proconvertine Stuart B (PPSB) and protein C and S.

^c Oxytocin (n = 51), sulprostone (n = 36), methylergonovine (n = 34), misoprostol (n = 40), intracavitary prostaglandins (n = 12).

 d Bakri balloon (n = 15), B-Lynch (n = 3), intrauterine packing (n = 2), Bakri balloon and B-Lynch (1).

^e Norepinephrine (2), ephedrine (1), epinephrine (1).

Table 3

Operational and medical characteristics of the interhospital transfer (HEMS) of patients with postpartum haemorrhage (n = 69).

| Nocturnal intervention | ns, n (%) | | 15 (22) |
|-------------------------------------|---|--|------------|
| Departure time (min) | | | |
| | Overall | | 7 (5–10) |
| | Daytime | | 5 (4–9) |
| | Night-time ^a | | 12 (9-13) |
| Time on site (min), m | iedian (IQR) | | 27 (22-32) |
| Time to destination (| min), median (IQR) | | 11 (9-12) |
| Total prehospital time | e (min), median (IQR) | | 58 (50-65) |
| Patient already intub | Patient already intubated before transfer | | 23 (32) |
| Treatments administrated during the | | | |
| flight, n (%) | | | |
| | Vascular filling | | 64 (96) |
| | Oxytocin IV | | 22 (32) |
| | Oxygen | | 39 (56) |
| | PRBC | | 21 (30) |
| | Vasoactive drugs ^b | | 12 (14) |
| | Fentanyl ^c | | 9 (13) |
| | FFP | | 8 (12) |
| | Tranexamic acid | | 6 (9) |
| | | | |

FFP = fresh frozen plasma; HEMS = helicopter emergency medical service; IQR = interquartile range; PRBC = packed red blood cells; IV = intravenous.

^a P < 0.001 between day and night.

^b Ephedrine (n = 3), neosynephrine (n = 7), epinephrine (n = 2).

^c Median dose (IQR) of 100 μ g (IQR 100–200).

cess rate of UAE is lower for unstable patients and a transfer for UAE should therefore ideally be considered in patients without signs of haemodynamic instability [7,29].

Pharmacological treatments and blood supplies

In our study, most treatments initiated at the transferring hospital were continued, and many treatments were initiated or repeated during HEMS transfer, including uterotonics, blood components, and tranexamic acid. Similar to the case for trauma, it is advised that medical treatment, including blood transfusion,

Table 4

Evolution of the vital parameters and laboratory values of patients with postpartum haemorrhage between the transferring and receiving hospitals (n = 69).

| | Before transfer | At hospital | p value |
|--|-----------------------|---------------------|---------|
| Vital parameters | | | |
| CRT > 2 s, n (%) | 14 (22) | - | - |
| GCS, median (IQR) | 15 (3-15) | 15 (3-15) | - |
| $EtCO_2$ (mmHg), median (IQR) (p = 0.6) ^a | 37 (35–39.5) | 36 (34-39) | 0.81 |
| SpO ₂ , median (IQR) | 99 (97-100) | 99 (97-100) | 0.24 |
| HR (min^{-1}) , median (IQR) | 105 (94–124) | 104 (92-123) | 0.54 |
| $RR (min^{-1})$, median (IQR) | 16 (14–20) | 16 (14–19) | 0.05 |
| SBP (mmHg), median (IQR) | 113 (95–128) | 111 (100–125) | 0.60 |
| Shock index, median (IQR) | 1 (0.8–1.1) | 0.9 (0.8–1.1) | 0.41 |
| Temperature (°C), median (IQR) ^b | 36.5 (36-36.7) | _ | - |
| VAS ^c | 0 (0-3) | 0 (0-1) | 0.02 |
| Laboratory values | | | |
| Base excess $(mEq/L)^d$, median (IQR) | -7.45 (-11.2 to -5.9) | -4.9 (-7.1 to -2.9) | 0.20 |
| Hb (g/L), median (IQR) ^e | 79 (68–94) | 89.5 (75.9–101.5) | 0.14 |
| Lactate > 2 mmol/L, n (%) | 7 (88) | 31 (55) | - |
| Lactate (mmol/L), median (IQR) | 2.9 (2.1-6.8) | 2.1 (1.55-3.5) | 0.90 |

CRT = capillary refill time; EtCO₂ = end-tidal carbon dioxide; GCS = Glasgow Coma Scale; Hb = haemoglobin; HR = heart rate; IQR = interquartile range; RR = respiratory rate; SBP = systolic blood pressure; SpO₂ = blood oxygen saturation; VAS = visual analogue scale.

^a n = 16.

^b n = 6 observations.

^c Visual analogue scale to determine pain with a score of 1-10/10.

^d n = 9 observations.

^e Hb levels at hospital were lower than before transfer in 22 (40%) patients for whom this information was available. The highest decline in Hb levels were 43, 37 (n = 2), 30, 29, and 16 g/L.

Table 5

_

Hospital treatments of patients transferred for postpartum haemorrhage (n = 69).

| Hospital main 1st treatment, n(%) | | Hospital 2nd treatment, n(%) | |
|--|--|--|--|
| UAE None Curettage Surgical revision (without HY) Time to 1st hospital main treatment (minutes), median (IQR) | 36 (52) 15 (22) 6 (9) 12 (17) 35 (27-44) | UAE ^c None Surgical revision Hysterectomy ^d Time to 2nd hospital main treatment (minutes), median (IQR) | 8 (12) 58 (84) 2(3) 1(1) 360 (142–695) |
| Other hospital treatment, n (%) Uterotonic drugs ^a PRBC Vasoactive drugs Hypnotic drugs ^b Opiates FFP Tranexamic acid | | 30 (60) 21 (30) 15 (22) 12 (20) 9 (15) 8 (12) 6 (10) | |
| Maternal outcome 48-h outcome Alive, intermediate care unit hospitalization Alive, ward hospitalization Alive, transferred to another hospital Alive, ICU hospitalization Alive, discharged | | 31(45) 21 (30) 11(16) 5 (7) 1(1) | |
| ICU stay duration (days), n (%) <24 h 1 day 2 days 4 days 5 days 71 days ICU length of stay (days), median (IQR) Intermediate care length of stay (days), median (IQR) Hospital length of stay (days), median (IQR) Maternal mortality | | $46(68) \\ 17(25) \\ 3(4) \\ 1(1) \\ 1(1) \\ 1(1) \\ 0 (0-1) \\ 1 (1-2) \\ 4 (2-6) \\ 1 (1.4)$ | |
| Neonatal mortality | | 3 (6) | |

FFP: fresh frozen plasma; HY: hysterectomy; ICU: intensive care unit; IQR: interquartile range; PRBC: packed red blood cells; UAE: uterine artery embolization.

^a Sulprostone (n = 21), intracavitary prostaglandin (n = 8), oxytocin (n = 1).

^b Propofol (n = 7), Midazolam (n = 2).

^c After failure of surgical revision (n = 5), curettage (n = 2), and first embolization (n = 1).

^d After failure of embolization.

should be initiated in the transferring facility [33,34]. This is especially important for patients with PPH who are being transferred for UAE, as disseminated intravascular coagulation is linked to UAE failure and worse outcomes [25,26,28,33]. Notably, if given soon after bleeding onset, tranexamic acid is known to reduce the risk of death from blood loss in women with PPH [2,17,35,36].

Although the utility of tranexamic acid is widely known, in our study we found a very low proportion of women who received it; 34% is the overall percentage without taking into consideration the frequency for each individual year. The most important study demonstrating the effectiveness of tranexamic acid in patients with post-partum haemorrhage was published in 2007 [2]. If we split our population into two parts (before and after 2007), the administration rate of tranexamic acid was 17% for the first part of the study period and more than 40% for the second part. The administration rate was in either case under 50% and the reason was found to be, especially in the years after 2007, in the lack of knowledge of the drug, especially in a secondary hospital. After 2007 only five patients received tranexamic acid during the flight, one of them as a first dose.

Interestingly, uterine massage may be considered in our setting and is recommended by some guidelines [4,7], but it was not reported in our case series, although it may have been performed by an accompanying midwife.

Blood transfusion is a supportive treatment for haemodynamic instability. We found a tendency to under-transfuse, as less than half of the population received at least one transfusion of PRBC and only 16% received more than five despite the critical conditions. This can be explained both by the concept of under-triage, as explained earlier, and by the fact that transferring hospitals often have limited blood bank capabilities.

Transfer of unstable patients: pros and cons

The assessment of haemodynamic stability in PPH is, however, not straightforward. Blood loss estimation is probably an insufficient parameter: as visual estimation of blood loss has been shown to be inaccurate in PPH [7]. Our results nonetheless show that a substantial proportion of our patients transferred for UAE had the criteria for haemodynamic instability based on the SI. This parameter, suggested to assess the degree of hypovolemic shock [20], was notably >1 for 52% of patients [17,18,21]. Vasopressors, which are also an indicator of haemodynamic instability, were administered in 14% of our patients. In our setting, interhospital transfer of patients with PPH is an option, but it is also performed in situations of haemodynamically unstable patients. Other studies also report transferring patients with PPH with haemodynamic instability [15,25,26,31], the proportion of these unstable patients being 22% [15] or 18%, [16] and thus half of the percentage shown in our study. The parameters of shock or hypoperfusion (SI, lactate levels, base excess levels) and haemoglobin levels were not significantly worse at hospital arrival compared with values before transfer. The patients' general conditions remained unchanged despite the seriousness of the situation, which may partially be explained by the relatively short transfer time, as well as the treatments administered during transfer. The safety of our practice seems further supported by the good outcome of our patients, as well as the absence of serious complications occurring during HEMS transfer. Although our conclusions may be hindered by the relatively low number of cases, our results suggest that there was no under-triage [37]. Under-triage would be represented by patients being transferred for PPH who had serious complications during transfer or at hospital arrival. The only patient who died after transfer was found to have abdominal bleeding rather than a gynaecological source of haemorrhage. On the other hand, our data may also suggest that some unstable patients may have undergone rescue peripartum HY in the secondary hospital, which could have been avoided by transferring the patient for UAE. The existence and extent of such over-triage [37], however, cannot be determined from our data.

The transfer of a haemodynamically unstable patient is usually contraindicated unless a medical necessity exists (unavailable surgery in the transferring hospital) [33]. Many hospitals have maternal and obstetric services available to offer definitive surgical treatment (HY), but do not have the capacity for UAE [7]. Although in some other medical conditions, bringing the treatment to the patient either in the hospital [32] or in the community [34] may be an option, this is not the case for UAE. Such interhospital transfer needs to carefully balance the risk to the mother's life with the benefit of preserving fertility, which may be an extremely difficult and complex decision.

Guidelines have also been advocated for the selection and transfer of patients with PPH to higher level centres [7,38,39].

A comprehensive system regarding interhospital transfer does not yet exist, but could be developed with the input of tertiary hospitals. Finally, the existing guidelines should also support the transfer of selected patients with PPH for UAE, despite instability criteria.

Limitations

The main limitation of our study pertains to its retrospective nature, which may have affected the quality and exhaustiveness of the data. This impact is probably limited, however, because of our access not only to the HEMS medical chart, but also to those from the transferring and receiving hospitals. Other limitations include the long duration of the study, as well as the relatively low number of cases. Conclusions about outcomes or major complications therefore need to be interpreted with caution. These limitations are characteristic of numerous infrequent medical conditions, including PPH, and are a major reason that most published studies on this topic are retrospective. Finally, we had no access to the cases with PPH that were not transferred, including those for whom HY may have been performed in the secondary hospital. Better knowledge of these cases would be necessary to comprehensively assess the PPH management process in the regional network.

Conclusions

Interhospital helicopter transfer of patients with PPH to a tertiary hospital in order to undergo UAE seems to be safe, despite a significant proportion of patients having signs of haemodynamic instability. Our practice, as well as those of many other clinicians, contrasts with the guidelines that usually reserve transfer for those patients with PPH who are haemodynamically stable. Decision criteria still need to be developed. In deciding to transfer a patient with PPH to a tertiary hospital in order to receive UAE, the team needs to take into account not only the benefit of avoiding HY as a means to preserve future chances of pregnancy, but also the potential adverse maternal outcome secondary to haemorrhagic shock. This decision should be a multidisciplinary one that is shared with the transferring team in the context of a regional network that includes pre-established procedures and guidelines.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

World Health Organization (WHO). WHO Guidelines Approved by the Guidelines Review Committee. WHO recommendations for the prevention and treatment of postpartum haemorrhage, Geneva; 2012.

S. Giacalone, A. Kottmann, V. Darioli et al.

- [2] Shakur H, Roberts I, Fawole B, et al. (WOMAN Trial Collaborators). Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389(10084):2105–16.
- [3] Deneux-Tharaux C, Bonnet M-P, Tort J. Épidémiologie de l'hémorragie du postpartum. J Gynécol Obstétrique Biol Reprod 2014;43(10):936–50.
- [4] Schlembach D, Helmer H, Henrich W, et al. Peripartum Haemorrhage, Diagnosis and Therapy. Guideline of the DGGG, OEGGG and SGGG (S2k level, AWMF Registry No. 015/063, March 2016). Geburtshilfe Frauenheilkd 2018;78(4):382–99.
- [5] Say L, Chou D, Gemmill A, Tunçalp Ö, Moller A-B, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health 2014;2(6):e323–33.
- [6] Surbek D, Irion O, Hess T, Drack G. Options actuelles pour le traitement de l'hémorragie postpartum ; Recommandations de la SGGG, avis d'expert No 26, Société Suisse de Gynécologie et Obstétrique (SGGG); 2012.
- [7] Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol 2017;130:4e168–e186.
- [8] Soro MP, Denys A, de Rham M, Baud D. Short & long term adverse outcomes after arterial embolisation for the treatment of postpartum haemorrhage: a systematic review. Eur Radiol 2017;27(2):749–62.
- [9] Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PFA. Fa Van Look P. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367 (9516):1066–74.
- [10] Gayat E, Resche-Rigon M, Morel O, Rossignol M, Mantz J, Nicolas-Robin A, et al. Predictive factors of advanced interventional procedures in a multicentre severe postpartum haemorrhage study. Intensive Care Med 2011;37 (11):1816–25.
- [11] Pelage J-P, Fohlen A, Le Pennec V. Place de l'embolisation artérielle en cas d'hémorragie du post-partum. J Gynécol Obstétrique Biol Reprod 2014;43 (10):1063–82.
- [12] Aoki M, Tokue H, Miyazaki M, Shibuya K, Hirasawa S, Oshima K. Primary postpartum hemorrhage: outcome of uterine artery embolization. Br J Radiol 2018;91(1087):20180132.
- [13] Deux JF, Bazot M, Le Blanche AF, et al. Is selective embolization of uterine arteries a safe alternative to hysterectomy in patients with postpartum haemorrhage? AJR Am J Roentgenol 2001;177:145–9.
- [14] Ganguli S, Stecker MS, Pyne D, Baum RA, Fan C-M. Uterine artery embolization in the treatment of postpartum uterine hemorrhage. J Vasc Interv Radiol 2011;22(2):169–76.
- [15] Kaye R, Shewry E, Reid C, Burns B. The obstetric caseload of a physician-based helicopter emergency medical service: case review and recommendations for retrieval physician training. Emerg Med J 2014;31(8):665–8.
- [16] Darioli V, Taffé P, Carron PN, et al. Evaluation of the discriminative performance of the prehospital National Advisory Committee for Aeronautics score regarding 48-h mortality. Eur J Emerg Med 2019.
- [17] Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 2019;23(1). <u>https://doi.org/10.1186/ s13054-019-2347-3</u>.
- [18] Rady MY, Smithline HA, Blake H, Nowak R, Rivers E. A comparison of the shock index and conventional vital signs to identify acute, critical illness in the emergency department. Ann Emerg Med 1994;24(4):685–90.
- [19] El Ayadi AM, Nathan HL, Seed PT, Butrick EA, Hezelgrave NL, Shennan AH, et al. Vital sign prediction of adverse maternal outcomes in women with hypovolemic shock: the role of shock index e0148729. PLoS ONE 2016;11 (2). <u>https://doi.org/10.1371/journal.pone.0148729</u>.
- [20] Kheirbek T, Martin TJ, Cao J, Hall BM, Lueckel S, Adams CA. Prehospital shock index outperforms hypotension alone in predicting significant injury in trauma patients. Trauma Surg Acute Care Open 2021;6(1):e000712. <u>https:// doi.org/10.1136/tsaco-2021-000712</u>.
- [21] Kramer MS, Berg C, Abenhaim H, Dahhou M, Rouleau J, Mehrabadi A, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol 2013;209(5):449.
- [22] De la Cruz CZ, Coulter M, O'Rourke K, Mbah AK, Salihu HM. Post-traumatic stress disorder following emergency peripartum hysterectomy. Arch Gynecol Obstet 2016;294(4):681–8.
- [23] Kaelin Agten A, Passweg D, von Orelli S, Ringel N, Tschudi R, Tutschek B. Temporal trends of postpartum haemorrhage in Switzerland: a 22-year retrospective population-based cohort study. Swiss Med Wkly 2017;147:w14551.
- [24] Michelet D, Ricbourg A, Gosme C, Rossignol M, Schurando P, Barranger E, et al. Emergency hysterectomy for life-threatening postpartum haemorrhage: risk factors and psychological impact. Gynecol Obstet Fertil 2015;43(12):773–9.
- [25] Cheong JY, Kong TW, Son JH, Won JH, Yang JI, Kim HS. Outcome of pelvic arterial embolization for postpartum hemorrhage: a retrospective review of 117 cases. Obstet Gynecol Sci 2014;57(1):17–27.
- [26] Kim Y-J, Yoon CJ, Seong NJ, Kang S-G, An S-W, Kim Y-S, et al. Failed pelvic arterial embolization for postpartum hemorrhage: clinical outcomes and predictive factors. J Vasc Interv Radiol 2013;24(5):703–9.
- [27] Ruiz Labarta FJ, Pintado Recarte MP, Alvarez Luque A, Joigneau Prieto L, Perez Martín L, Gonzalez Leyte M, et al. Outcomes of pelvic arterial embolization in the management of postpartum haemorrhage: a case series study and systematic review. Eur J Obstet Gynecol Reprod Biol 2016;206:12–21.

European Journal of Obstetrics & Gynecology and Reproductive Biology 268 (2022) 48-55

- [28] Poujade O, Zappa M, Letendre I, Ceccaldi PF, Vilgrain V, Luton D. Predictive factors for failure of pelvic arterial embolization for postpartum hemorrhage. Int J Gynaecol Obstet 2012;117(2):119–23.
- [29] Kim STH, Lee HH, Kim JM, Ryu AL, Chung SH, Lee WS. Uterine artery embolization for primary postpartum hemorrhage. Iran J Reprod Med 2013;11(6):511–8.
 [30] Lee HY, Shin JH, Kim J, Yoon H-K, Ko G-Y, Won H-S, et al. Primary postpartum
- [30] Lee HY, Shin JH, Kim J, Yoon H-K, Ko G-Y, Won H-S, et al. Primary postpartum hemorrhage: outcome of pelvic arterial embolization in 251 patients at a single institution. Radiology 2012;264(3):903–9.
- [31] Ulrich CL, Utarnachitt RB, Danielson K, Pieri A, Whitley S, Latimer AJ. Postpartum Hemorrhage With Cardiorespiratory Collapse Transported From a Rural Hospital. Air Med J 2019;38(6):440–1.
- [32] Wilhelm MJ, Inderbitzin DT, Reser D, et al. Outcome of inter-hospital transfer of patients on extracorporeal membrane oxygenation in Switzerland. Swiss Med Wkly 2019;17:149. w20054.
- [33] Rotondo MF, Cribari C, Smith RS, et al. Resources for Optimal care of the injured patient. 6 ed. American College of Surgeons; 2014.
- [34] Bougouin W, Dumas F, Lamhaut L, et al. Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest: a registry study. Sudden Death Expertise Center investigators. Eur Heart J 2020;41(21):1961–71.
- [35] World Health Organization WHO model lists of essential medicines. 21th ed.; 2019. https://www.who.int/medicines/en/>
- [36] Vogel JP, Oladapo OT, Dowswell T, Gülmezoglu AM. Updated WHO recommendation on intravenous tranexamic acid for the treatment of postpartum haemorrhage. Lancet Global Health 2018;6(1):e18–9.
- [37] Di Rocco D, Pasquier M, Albrecht E, Carron P-N, Dami F. HEMS inter-facility transfer: a case-mix analysis. BMC Emerg Med 2018;18(1). <u>https://doi.org/ 10.1186/s12873-018-0163-8</u>.
- [38] Rossignol M, Rozenberg A. Inter-hospital transfer for severe postpartum haemorrhage. J Gynecol Obstet Biol Reprod (Paris) 2014;43(10):1123–32.
- [39] Schlembach D, Mörtl MG, Girard T, Arzt W, Beinder E, Brezinka C, et al. Management der postpartalen Blutung (PPH): Algorithmus der Interdisziplinären D-A-CH-Konsensusgruppe PPH (Deutschland – Österreich – Schweiz). Der Anaesthesist 2014;63(3):234–42.



Dr Sylvia Giacalone, pre-hospital and in-hospital emergency medicine specialist.



Dr Med Alexandre Kottmann, pre-hospital and inhospital emergency medicine specialist, intensive care specialist.



Dr Med Vincent Darioli, pre-hospital and in-hospital emergency medicine consultant.

S. Giacalone, A. Kottmann, V. Darioli et al.

European Journal of Obstetrics & Gynecology and Reproductive Biology 268 (2022) 48-55



Prof Pierre-Nicolas Carron, Director of Emergency Department, Lausanne University Hospital.



Dr Roland Albrecht, Medical Director of the Swiss air ambulance service Rega.



Prof David Desseauve, gynaecology-obstetric consultant, university professor.



Dr Med Mathieu Pasquier, pre-hospital and in-hospital emergency medicine consultant, university professor.